Thin
1 / 1
Bremelanotide is a synthetic melanocortin receptor agonist. Unlike typical erectile dysfunction medications that target blood flow, it regulates libido by acting directly on the central nervous system, specifically the hypothalamus.
No, its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug.
Currently, the drug is administered via subcutaneous injection. While intranasal formulations were explored, their development has progressed slowly.
In 2019, its branded drug Vyleesi was approved by the U.S. FDA specifically for the treatment of acquired and generalized sexual interest/arousal disorders in premenopausal women.
It has potential therapeutic effects for men, especially for male erectile dysfunction (for those who cannot use standard drugs like nitrates) and low libido. However, these applications are still under main research.
The most common side effects include nausea and flushing, along with a risk of increased blood pressure. Other challenges include the inconvenience of subcutaneous injections and market stigma surrounding sexual dysfunction.
